Abstract: A rapid, specific and sensitive high-performance liquid chromatographic method for the determination of famotidine in human plasma has been developed. Famotidine and the internal standard were chromatographically separated from plasma components using a Lichrocart Lichrospher 60 RP selec B cartridge for solid-phase separation with a mobile phase composed of 0.1 % (v/v) triethylamine in water (pH 3) and acetonitrile (92:8, v/v). UV detection was set at 270 nm. The calibration curve was linear in the concentration range of 10.0 -350.0 ng mL -1 . The method was implemented to monitor the famotidine levels in patient samples.
INTRODUCTION
The description of the selective histamine H 2 -receptor blockade by Black in 1970 was a landmark in the history of pharmacology and set the stage for the modern approach to the treatment of acid-peptic disease, which until then had relied almost entirely on acid neutralization in the lumen of the stomach. The most prominent effects of H 2 -receptor antagonists are on basal acid secretion; less profound but still significant is the suppression of stimulated (feeding, gastrin, hypoglycemia, or vagal stimulation) acid production. 1 Famotidine is a well known histamine H 2 -receprot antagonist and highly effective and useful in the treatment of peptic ulcers. The absorption is rapid but incomplete in the gastro-intestinal tract with peak concentrations in the plasma occurring about 2 h after oral administration. Famotidine is weakly bound, about 15 to 20 %, to plasma proteins. Most of the drug is eliminated unchanged in the urine, but a small amount of famotidine is metabolised in the liver to famotidine S-oxide. 2 Therefore, the determination of famotidine concentrations in biological samples is of particular interest in pharmacokinetic studies.
Several high-performance liquid chromatography methods have been developed for measuring the famotidine concentration in pharmaceutical preparations. [3] [4] [5] [6] [7] A number of assay methods for famotidine in biological fluids have been reported. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Some authors have investigated the possibility of the determination of famotidine in plasma or urine after its separation and concentration by liquid-liquid extraction using ethyl acetate as the solvent 8, 9 or a two-step liquid extraction using diethyl ether and ethyl acetate. 10 However, the disadvantage of these methods employing liquid-liquid extraction of famotidine from biological fluids with ethyl acetate is that they give highly variable and relatively low recoveries (20-60 %) and therefore some authors suggested solid-phase extraction for sample pre-treatment.
Many investigators have performed the separation of famotidine from plasma with solid-phase extraction on different cartridges such as silica and C 18 -bonded silica. [11] [12] [13] Sample preparation performed on this kind of solid-phase cartridges unsatisfactory values for the recovery and poor separation of famotidine from the interfering plasma matrix.
Also, the isolation of the drug and elimination of endogenous plasma interferences with strong cation exchanger (SCX) solid-phase cartridges has been reported. [14] [15] [16] Zhong et al. 14, 15 proposed methods for the separation of famotidine from plasma samples using an SCX cartridge for solid-phase extraction and its determination with normal-phase liquid chromatography/tandem mass spectrometry 14 and column switching technique with UV detection. 15 Guo et al. 17 proposed the direct injection of plasma samples to determine famotidine in plasma using the HPLC column switching technique. This method involves direct injection of plasma to an extraction column for sample clean-up followed by switching onto an analytical column. The only disadvantages of this method is the high reagent consumption and a HPLC system with two pumps.
The aim of this work was develop a solid-phase extraction method for the elimination of plasma endogenous interferences on the determination of famotidine in human plasma. Namely, continuing our work on the development of solid-phase extraction methods for the separation of drugs from the plasma endogenous interferences, 16, 18 in this paper a new method for the determination of famotidine in plasma samples using the solid-phase extraction technique on RP-select B cartridges is proposed. In order to fulfil the aim, the method was first developed for the separation of and determination of famotidine concentrations using the internal standard method by optimising the experimental parameters and determining the linearity for the investigated drug. Then, the method for the determination of famotidine concentrations was validated by evaluating recovery, selectivity, linearity, precision and accuracy. Finally, the method was used for the determination of famotidine in patient plasma samples.
EXPERIMENTAL

Reagents and chemicals
Famotidine and the internal standard (I.S.) 3-[({2-[(aminoiminomethyl)amino]-4-thiazolyl}-methyl)thio]-propanamide, were kindly supplied by Select Chemie (Switzerland) and KRKA Pharmaceuticals (Slovenia), re-spectively. Acetonitrile and methanol were purchased from Across Organics (Belgium), o-phosphoric acid, potassium dihydrogen phosphate, sodium carbonate, acetic acid, sodium hydroxide and triethylamine were obtained from Merck (Germany). All used reagents were of analytical grade except acetonitrile and methanol, which were HPLC grade. Cartridges for solid-phase extraction were purchased from Merck (Germany).
Chromatographic system
The HPLC analysis was carried out on a Perkin-Elmer liquid chromatography system (USA) consisting of a pump LC series 200, autosampler LC ISS Series 200, diode array detector LC 235 C and column oven model 101. The chromatographic system was controlled by the software package Turbochrom Version 4.1. plus and the UV-spectrometric data are produced by the program TurboScan Version 2.0. The analytical column was LichroCart Lichrospher 60 RP-select B, 250´4 mm I.D., 5 mm particle size with a matched guard column (Merck, Germany). The mobile phase consisted of 0.1 % triethylamine (pH 3 adjusted with a very small amount of o-phosphoric acid) -acetonitrile (92:8, v/v). The mobile phase was filtered, degassed with helium and delivered at a flow-rate 1.2 mL min -1 . All experiments were carried out at ambient temperature, approximately 25 ºC.
Preparation of standard solutions and plasma samples
Stock solutions of famotidine and I.S. were prepared at a concentration 1000 mg mL -1 by dissolving appropriate amounts in 0.1 % (v/v) acetic acid. These solutions were stored at 4 ºC and no change in stability over a period of 1 month was observed. The working solutions were prepared by diluting appropriate portions of these solutions with distilled water.
Human plasma was prepared from heparinized whole blood samples. The blood samples were collected from healthy volunteers and stored at -20 ºC. After thawing, the samples were spiked daily with working solutions of famotidine and internal standard.
Sample preparation
A solid-phase extraction vacuum manifold (Merck) was used for the sample preparation. Satisfactory values of the recovery of famotidine and the I.S. were obtained with a single extraction using a RP select B solid phase cartridge (200 mg) for the isolation of the drugs from the plasma samples. Before analysis the plasma samples (0.9 mL) spiked with 100 ml of I.S. (20 mg mL -1 ) were buffered with 1 mL of 0.1 mol L -1 Na 2 CO 3 solution (pH 10 adjusted with NaOH). The cartridge was conditioned sequentially using 2 mL of methanol and 2 mL of water. The buffered plasma sample was introduced onto the cartridge under vacuum at 5 psi. Water (4 mL) was used to rinse the cartridge. The analytes were eluted with 2 mL methanol. The eluate was evaporated to dryness under N 2 for about 20 min at 40 ºC. After redissolving the residue in 150 mL of 0.017 mol L -1 CH 3 COOH, a volume of 120 mL was injected into the HPLC system.
Extraction recovery
Recovery studies were performed by analysing plasma samples spiked with famotidine at two concentration levels. Three replicate samples for each concentration were extracted and chromatographed. The extraction recoveries were calculated by comparing the peak height of famotidine and internal standard obtained for plasma samples (n = 3 for each level for famotidine, n = 6 for internal standard) with those resulting from the direct injection (n = 3, working solutions) of the theoretical amount of either famotidine or internal standard (= 100 % recovery).
Assay validation for famotidine
Linearity. Five calibration solutions of famotidine were prepared by serial dilution of the stock solution and spiking them into drug-free human plasma. The standard samples were prepared according to the procedures as unknown samples. The calibration curve was constructed by analysing a series of plasma calibration samples spiked with famotidine to obtain concentrations ranging from 10.0 to 350.0 ng mL -1 . The chromatograms were evaluated on the basis of the famotidine/I.S. ratios of the peak heights. The regression equation was calculated by the least-squares method.
Precision, accuracy and reliability
The intra-and inter-day precision was determined by analysing the spiked plasma samples of each concentration used for the construction of the calibration curve on three different days. The mean, standard deviations, RSD of the intra-and inter-day experiments were calculated.
The intra-and inter-day accuracy was determined by measuring plasma quality control samples of low, middle and high concentration levels of famotidine. The relative error of the mean predicted concentration compared with the nominal concentration was determined.
The reliability was tested on a second HPLC column of the same type by determining the linearity, precision and accuracy. The linearity was performed at five concentration points for famotidine in human plasma in the concentration range from 10.0 to 350.0 ng mL -1 . Intra-dey precision and accuracy were determined by measuring three series of plasma quality control samples.
Stability evaluation
The stability of famotidine in plasma was investigated using spiked samples at two different concentration levels prepared in duplicate. The spiked samples were analysed after different storage conditions: immediately, after staying in an autosampler for 2 and 24 h, after one and two freeze/thaw cycles and after one month sorage at -20 ºC. The stability was determined by comparing the nominal concentration of famotidine in the samples analysed immediately with those analysed after different storage conditions.
RESULTS AND DISCUSSION
Method development
A series of studies were conducted in order to develop a convenient and easy-to-use method for the quantitative analysis of famotidine in human plasma. Several HPLC method variables with respect to their effect on the separation of famotidine and internal standard from the matrix were investigated. In the extensive preliminary experiments, various column packings including C8, C18 and RP-select B of different lengths and particle sizes were tested. The results of this investigation showed that when the separation was performed on C8 and C18 columns the investigated drugs showed peak tailing. The peak tailing may be attributed to hydrogen bonding between the free silanols of the stationary phase and the amino groups of the investigated drugs. The final choice of the stationary phase giving satisfying peak shape, resolution and run time was a Lichrocart Lichrospher 60 RP-select B, 250´4 mm I.D. (5 mm, particle size). Also, a series of aqueous mobile phases with different pH values in combination with different modifiers including acetonitrile, methanol and triethylamine (TEA) with different volume fractions were tested. The elution was monitored over the whole UV region and the wavelength of 270 nm exhibited the best detection.
The amount of organic modifier present in the mobile phase will influence analytes that are retained predominantly by adsorption onto the stationary phase. Figure 1 shows the results that were obtained when the mobile phase contained 0.1 % (v/v) TEA and acetonitrile in the concentration range from 5 % to 15 % with the pH adjusted to 3 with a very small amount of concentrated o-phosphoric acid. This data was used to determine an optimal amount of organic modifier that should be used for the separation of famotidine and the I.S. The best results (good separation between two peaks, short time of analysis) were obtained when the percentage of acetonitrile in the mobile phase was 8 %.
An additional study was also done to check the effect that the percentage of TEA in the mobile phase had on the retention of the analytes. Also, the effect of pH on the retention of the analytes and their separation was observed over the pH range 2.5-6.0 using 0.1 % TEA solution. The obtained results are shown in Fig. 3 , which it can be seen that the retention of famotidine and I.S. decreased with decreasing pH of the mobile phase. A good separation of the investigated drugs and short time of analysis were obtained when the pH of the mobile phase was 3.
From these data it was determined that mobile phase containing 0.1 % TEA and 8 % acetonitrile with a pH of 3 would provide good retention of famotidine and the internal standard as well as an acceptable runtime for the separation of less that 8 min.
Typical chromatograms of standard solutions of famotidine and internal standard pro- duced by the developed HPLC method are shown in Fig. 4a The retention time of famotidine and of the internal standard are 4.2 and 5.1 min, respectively. In addition, different cartridges for solid phase extraction (C18, TSC, SCX and RP-select B) were tested in order to determine the satisfactory values of the recovery of famotidine and internal standard. The results from this investigation shows that solid-phase extraction without any pre-treatment of the plasma sample results in poor separation of the investigated drugs from the plasma endogenous interference of the plasma. Therefore, in order to improve the extraction procedure, the plasma samples were buffered at volume ratio of 1:1 with 0.1 mol L -1 solutions of Na 2 CO 3 (pH 10), KH 2 PO 4 (pH 3) or citric acid (pH 2.5) before being introduced onto the cartridges for solid-phase extraction. It was found that satisfactory values of the recovery of famotidine and I.S. were obtained when the plasma samples were buffered with Na 2 CO 3 solution and extracted using TSC, C18 and RP-select B cartridges. Also, satisfactory values for the recovery of famotidine and I.S. were obtained when plasma samples, buffered with citric acid, were extracted with SCX columns. The results from this investigation are given in Table I . On the other hand, solid-phase extraction on TSC and C18 columns gave an interfering peak at the retention time of the internal standard. Interfering peaks were found at the retention times of investigated analytes except when the solid-phase extraction was performed on RP-select or SCX cartridges. Therefore, in this study, the determination of famotidine in plasma samples was performed after their preparation with Na 2 CO 3 solution and extraction on RP select B cartridges. Typical chromatograms of the blank human plasma (b) and plasma sample spiked with famotidine and internal standard (c) are shown in Fig. 4 . No interfering peaks were found at the retention times of the investigated analytes.
The developed HPLC method was used for the analysis of plasma samples of patients after oral administration of famotidine. Typical chromatograms of the plasma samples of patients prepared according the procedures for sample preparation after a single 40 mg oral dose of famotidine are shown in Fig. 5 .
Method validation
Linear detector response for the peak-height ratios of famotidine to internal standard was observed in the concentration range from 10.0 to 350.0 ng mL -1 with a correlation coefficient of 0.9999. The respective regression equation for famotidine obtained after sample preparation using solid-phase extraction was: y = 0.0047 g -0.0068.
Under the employed experimental conditions, the lower limit of detection was 4 ng mL -1 at a signal-to-noise ratio of 3. The limit of quantification was defined as the lowest amount detectable with a precision of less than 15 % (n = 5) and an accuracy of ± 15 % (n = 5). The limit of quantification was found to be 10 ng mL -1 . The results of the study of the validation of the method are presented in Tables II and  III . The intra-and inter-day variations of the method throughout the linear range of concentrations are shown in Table II . The intra-and inter-day reproducibilities expressed as relative standard deviation (RSD) were found to be 0.53-6.45 %, indicating good precision of the proposed method. The indication of the accuracy was based on the calculation of the relative error of the mean observed concentration as compared to the nominal concentration. The accuracy data are presented in Table III . The relative errors at all three studied concentrations are less than 8.8 % and it is obvious that the method is remarkably accurate which ensures that reliable results can be obtained. The reliability was tested using a second HPLC column of the same type by determining the linearity, precision and accuracy. The linearity test was performed at five concentration points for famotidine in human plasma in the concentration range from 10.0 to 350.0 ng mL -1 . The regression equation was: y = 0.0047 g -0.0155, with a correlation coefficient of 0.9992. The relative standard deviations at all three studied concentrations of famotidine were less than 2.82 %. The relative errors ranged from 0.6 to 6.07 % of the nominal concentrations of the investigated drug. As can be seen, the results of this assessment are very similar to those obtained by the previous investigation on the first HPLC column. That means that this HPLC method for the determination of famotidine in spiked human plasma samples is reliable.
The results from the stability studies show that relative errors for the two different concentrations studied ranged from 0.14 to 11.4 % and it is obvious that famotidine added to plasma is stable under different storage conditions.
CONCLUSIONS
The developed HPLC method employing solid-phase extraction for sample preparation, is simple and convenient for the determination of famotidine in plasma samples. The typical assay time is about 8 min. Famotidine and the internal standard have been successfully separated. The proposed method is simply, rapid and provides efficient clean up of the complex biological matrix and high recovery of famotidine. The validation data demonstrate good precision and accuracy, which proves the reliability of the proposed method. Finally, the method has been implemented to monitor famotidine levels in clinical samples. Razvijena je brza, specifi~na i osetqiva metoda za odre|ivawe famotidina u qudskoj plazmi kori{}ewem te~ne hromatografije visokog razlagawa. Famotidin i interni standard su hromatografski razvojeni od drugih komponenata plazme pomo}u Lichrocart Lichrospher 60 RP select B patrone za separaciju pomo}u~vrste faze, uz kori{}ewe 0,1 % (v/v) trietilamina u vodi (pH 3) i acetonitrila (92:8 %, v/v) kao pokretne te~ne faze. UV detekcija je vr{ena na 270 nm. Kalibracioni dijagram je linearan u oblasti koncentacija 10,0 -350,0 ng mL -1 . Metoda je primewena za pra}ewe nivoa koncentracije famotidina u uzorcima uzetim od pacijenata. (Primqeno 17. aprila 2003) 
